BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

2406

524558

NEULANDLAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NEULAND LAB LTD. performance

Today’s low

Today’s high

₹ 11906.00 ₹ 12502.00
₹ 11992.00

52 week low

52 week high

₹ 5540.10 ₹ 18100.00
₹ 11992.00

Open Price

₹ 12340.00

Prev. Close

₹ 12278.00

Volume (Shares)

29269.00

Total traded value

₹ 3509.93

Upper Circuit

₹ 14733.00

Lower Circuit

₹ 9823.00

info

NEULAND LAB LTD. Share Price Update

As of the latest trading session, NEULAND LAB LTD. share price is currently at ₹ 11992, which is down by ₹ -286.00 from its previous closing. Today, the stock has fluctuated between ₹ 11906.00 and ₹ 12502.00. Over the past year, NEULAND LAB LTD. has achieved a return of 57.92 %. In the last month alone, the return has been 4.42 %. Read More...

NEULAND LAB LTD. fundamentals


  • Market cap (Cr)

    15,385.60

  • P/E Ratio (TTM)

    51.60

  • Beta

    0.94

  • Book Value / share

    1,081.52

  • Return on equity

    26.48%

  • EPS (TTM)

    186.59

  • Dividend yield

    0.12%

  • Net profit/quarter (Cr)

    101.39

info icon alternate text
  • Market cap (Cr)

    15,443.21

  • P/E Ratio (TTM)

    51.60

  • Beta

    0.98

  • Book Value / share

    1,081.52

  • Return on equity

    26.48%

  • EPS (TTM)

    186.59

  • Dividend yield

    0.12%

  • Net profit/quarter (Cr)

    101.39

info icon alternate text

NEULAND LAB LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 398.03
Operating Expense 330.17
Net Profit 101.39
Net Profit Margin (%) 25.47
Earnings Per Share (EPS) 79.03
EBITDA 146.06
Effective Tax Rate (%) 20.50
Particulars SEP 2024 (Values in Cr)
Revenue 310.84
Operating Expense 266.63
Net Profit 31.96
Net Profit Margin (%) 10.28
Earnings Per Share (EPS) 24.91
EBITDA 65.67
Effective Tax Rate (%) 34.15
Particulars JUN 2024 (Values in Cr)
Revenue 439.60
Operating Expense 334.73
Net Profit 98.34
Net Profit Margin (%) 22.37
Earnings Per Share (EPS) 76.65
EBITDA 149.26
Effective Tax Rate (%) 24.53
Particulars MAR 2024 (Values in Cr)
Revenue 385.01
Operating Expense 298.29
Net Profit 67.61
Net Profit Margin (%) 17.56
Earnings Per Share (EPS) 52.70
EBITDA 112.15
Effective Tax Rate (%) 26.57
Particulars DEC 2023 (Values in Cr)
Revenue 392.83
Operating Expense 291.15
Net Profit 80.70
Net Profit Margin (%) 20.54
Earnings Per Share (EPS) 62.90
EBITDA 122.66
Effective Tax Rate (%) 22.23
Particulars MAR 2024 (Values in Cr)
Revenue 1558.58
Operating Expense 1170.36
Net Profit 299.60
Net Profit Margin (%) 19.22
Earnings Per Share (EPS) 233.51
EBITDA 474.46
Effective Tax Rate (%) 25.24
Particulars MAR 2023 (Values in Cr)
Revenue 1191.20
Operating Expense 985.74
Net Profit 163.12
Net Profit Margin (%) 13.69
Earnings Per Share (EPS) 127.14
EBITDA 281.06
Effective Tax Rate (%) 24.20
Particulars MAR 2022 (Values in Cr)
Revenue 951.08
Operating Expense 871.41
Net Profit 63.53
Net Profit Margin (%) 6.67
Earnings Per Share (EPS) 49.74
EBITDA 144.26
Effective Tax Rate (%) 22.27
Particulars MAR 2021 (Values in Cr)
Revenue 936.91
Operating Expense 848.05
Net Profit 80.29
Net Profit Margin (%) 8.56
Earnings Per Share (EPS) 62.58
EBITDA 162.54
Effective Tax Rate (%) 23.50
Particulars MAR 2020 (Values in Cr)
Revenue 762.71
Operating Expense 714.10
Net Profit 15.88
Net Profit Margin (%) 2.08
Earnings Per Share (EPS) 12.38
EBITDA 105.35
Effective Tax Rate (%) 69.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 993.66
ROE % 26.38
ROCE % 33.01
Total Debt to Total Equity 0.10
EBITDA Margin 30.49
Particulars MAR 2023 (Values in Cr)
Book Value / Share 769.94
ROE % 17.84
ROCE % 20.58
Total Debt to Total Equity 0.20
EBITDA Margin 23.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 650.88
ROE % 7.85
ROCE % 9.23
Total Debt to Total Equity 0.26
EBITDA Margin 15.21
Particulars MAR 2021 (Values in Cr)
Book Value / Share 608.98
ROE % 9.48
ROCE % 11.10
Total Debt to Total Equity 0.30
EBITDA Margin 16.02
Particulars MAR 2020 (Values in Cr)
Book Value / Share 549.68
ROE % 2.30
ROCE % 7.56
Total Debt to Total Equity 0.35
EBITDA Margin 13.87
Particulars MAR 2024 (Values in Cr)
Book Value / Share 988.88
ROE % 26.48
ROCE % 33.13
Total Debt to Total Equity 0.10
EBITDA Margin 30.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 765.49
ROE % 17.90
ROCE % 20.64
Total Debt to Total Equity 0.20
EBITDA Margin 23.59
Particulars MAR 2022 (Values in Cr)
Book Value / Share 647.06
ROE % 7.86
ROCE % 9.24
Total Debt to Total Equity 0.26
EBITDA Margin 15.17
Particulars MAR 2021 (Values in Cr)
Book Value / Share 605.44
ROE % 9.49
ROCE % 11.12
Total Debt to Total Equity 0.30
EBITDA Margin 15.98
Particulars MAR 2020 (Values in Cr)
Book Value / Share 546.26
ROE % 2.27
ROCE % 7.55
Total Debt to Total Equity 0.35
EBITDA Margin 13.81
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 116.79
Total Assets 1832.56
Total Liabilities 1832.56
Total Equity 1282.70
Share Outstanding 12829889
Price to Book Ratio 6.35
Return on Assets (%) 16.37
Return on Capital (%) 21.98
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 59.10
Total Assets 1579.76
Total Liabilities 1579.76
Total Equity 994.09
Share Outstanding 12829889
Price to Book Ratio 2.35
Return on Assets (%) 10.35
Return on Capital (%) 14.66
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 20.35
Total Assets 1383.48
Total Liabilities 1383.48
Total Equity 840.50
Share Outstanding 12829889
Price to Book Ratio 1.59
Return on Assets (%) 4.61
Return on Capital (%) 5.96
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 19.39
Total Assets 1324.78
Total Liabilities 1324.78
Total Equity 786.45
Share Outstanding 12829889
Price to Book Ratio 3.45
Return on Assets (%) 6.08
Return on Capital (%) 8.43
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 46.98
Total Assets 1230.97
Total Liabilities 1230.97
Total Equity 709.95
Share Outstanding 12829889
Price to Book Ratio 0.52
Return on Assets (%) 1.31
Return on Capital (%) 1.7
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 115.28
Total Assets 1830.92
Total Liabilities 1830.92
Total Equity 1276.53
Share Outstanding 12829889
Price to Book Ratio 6.35
Return on Assets (%) 16.36
Return on Capital (%) 22.04
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 58.64
Total Assets 1579.33
Total Liabilities 1579.33
Total Equity 988.36
Share Outstanding 12829889
Price to Book Ratio 2.35
Return on Assets (%) 10.32
Return on Capital (%) 14.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 18.98
Total Assets 1382.12
Total Liabilities 1382.12
Total Equity 835.57
Share Outstanding 12829889
Price to Book Ratio 1.59
Return on Assets (%) 4.59
Return on Capital (%) 5.96
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 18.07
Total Assets 1323.52
Total Liabilities 1323.52
Total Equity 781.88
Share Outstanding 12829889
Price to Book Ratio 3.45
Return on Assets (%) 6.06
Return on Capital (%) 8.43
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 45.69
Total Assets 1229.74
Total Liabilities 1229.74
Total Equity 705.54
Share Outstanding 12829889
Price to Book Ratio 0.52
Return on Assets (%) 1.29
Return on Capital (%) 1.67
Particulars MAR 2024 (Values in Cr)
Net Income 401.43
Cash from Operations 372.78
Cash from Investing -149.68
Cash from Financing -69.28
Net change in Cash 42.20
Free Cash Flow 516.45
Particulars MAR 2023 (Values in Cr)
Net Income 215.74
Cash from Operations 280.83
Cash from Investing -61.49
Cash from Financing -135.79
Net change in Cash 39.91
Free Cash Flow 346.96
Particulars MAR 2022 (Values in Cr)
Net Income 82.16
Cash from Operations 80.88
Cash from Investing -95.51
Cash from Financing 37.72
Net change in Cash 2.59
Free Cash Flow 178.56
Particulars MAR 2021 (Values in Cr)
Net Income 105.33
Cash from Operations 194.63
Cash from Investing -84.42
Cash from Financing -113.66
Net change in Cash -8.72
Free Cash Flow 300.03
Particulars MAR 2020 (Values in Cr)
Net Income 52.92
Cash from Operations 62.02
Cash from Investing -48.67
Cash from Financing -5.48
Net change in Cash 3.18
Free Cash Flow 110.82
Particulars MAR 2024 (Values in Cr)
Net Income 400.76
Cash from Operations 371.62
Cash from Investing -149.67
Cash from Financing -69.28
Net change in Cash 41.10
Free Cash Flow 515.28
Particulars MAR 2023 (Values in Cr)
Net Income 215.21
Cash from Operations 282.09
Cash from Investing -61.49
Cash from Financing -135.79
Net change in Cash 41.23
Free Cash Flow 348.22
Particulars MAR 2022 (Values in Cr)
Net Income 81.73
Cash from Operations 80.93
Cash from Investing -95.52
Cash from Financing 37.72
Net change in Cash 2.60
Free Cash Flow 178.62
Particulars MAR 2021 (Values in Cr)
Net Income 104.96
Cash from Operations 194.46
Cash from Investing -84.41
Cash from Financing -113.65
Net change in Cash -8.79
Free Cash Flow 299.85
Particulars MAR 2020 (Values in Cr)
Net Income 52.49
Cash from Operations 61.33
Cash from Investing -48.67
Cash from Financing -5.47
Net change in Cash 2.47
Free Cash Flow 110.12
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

NEULAND LAB LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
11992.00 -2.32 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 12348.80
  • 26 Days 12191.00
  • 10 Days 12396.70
  • 50 Days 12268.30
  • 12 Days 12371.10
  • 100 Days 12538.40
  • 20 Days 12245.50
  • 200 Days 11903.90
12416.00 PIVOT

First Support

12022.00

First Resistance

12672.00

Second Support

11766.00

Second Resistance

13066.00

Third Support

11372.00

Third Resistance

13322.00

RSI

47.89

ADX

15.64

MACD

180.13

Williams % R

-53.07

Commodity Channel Index (CCI)

-3.05

Date

2025-04-30

Week

10942.00

Same Day

9312.00

Month

16114.00

1 Year

0.95

3 Year

0.85

Over 1 Month

4.42%

down

Over 1 Year

57.92%

down

Over 3 Months

-12.62%

down

Over 3 Years

108.47%

down

Over 6 Months

-13.28%

down

Over 5 Years

93.24%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

NEULAND LAB LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
34.24%
Promoter Holdings
32.67%
FII
22.11%
DII
10.96%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Davuluri Ownership Trust 3333352.0 (25.98%) Shareholding of Promoter and Promoter Group
Malabar India Fund Limited 739204.0 (5.76%) Public Shareholding
Mukul Mahavir Agrawal 400000.0 (3.12%) Public Shareholding
Hsbc Focused Fund 374846.0 (2.92%) Public Shareholding
Davuluri Sucheth Rao 257969.0 (2.01%) Shareholding of Promoter and Promoter Group
Ramamohan Rao Davuluri 209300.0 (1.63%) Shareholding of Promoter and Promoter Group
Siddharth Iyer 208172.0 (1.62%) Public Shareholding
Davuluri Saharsh Rao 207625.0 (1.62%) Shareholding of Promoter and Promoter Group
Icici Prudential Flexicap Fund 170723.0 (1.33%) Public Shareholding
Matthews India Fund 167437.0 (1.31%) Public Shareholding
Jupiter India Fund 165834.0 (1.29%) Public Shareholding
Kedia Securities Private Limited 130000.0 (1.01%) Public Shareholding
Davuluri Rohini Niveditha Rao 85780.0 (0.67%) Shareholding of Promoter and Promoter Group
Usha Rani Reddy Chevalla 33500.0 (0.26%) Shareholding of Promoter and Promoter Group
Gannabathula Venkata Krishna Rama Rao 31827.0 (0.25%) Shareholding of Promoter and Promoter Group
Gannabathula Veeravenkata Satyanarayanamurty 21222.0 (0.17%) Shareholding of Promoter and Promoter Group
Gannabathula Uma Bala 6409.0 (0.05%) Shareholding of Promoter and Promoter Group
Davuluri Vijaya Rao 5000.0 (0.04%) Shareholding of Promoter and Promoter Group
Suryanarayana M Siram 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Velugubanti S Prasadarao 100.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

NEULAND LAB LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Jul 2023 10.0 Final 12 Jul 2023 Equity shares
14 Jul 2022 5.0 Final 15 Jul 2022 Equity shares
29 Jun 2021 3.0 Final 01 Jul 2021 Equity shares
10 Nov 2020 2.0 Interim 11 Nov 2020 Equity shares
18 Feb 2020 2.0 Interim 20 Feb 2020 Equity shares
27 Jun 2019 1.2 Final 29 Jun 2019 Equity shares
04 Aug 2016 2.0 Final 08 Aug 2016 Equity shares
06 Aug 2015 1.5 Final 08 Aug 2015 Equity shares
16 Jun 2014 1.5 Final 18 Jun 2014 Equity shares
16 Jun 2014 1.5 Special 18 Jun 2014 Equity shares
24 Jul 2013 1.2 Final 26 Jul 2013 Equity shares
13 Jul 2009 3.5 Final 15 Jul 2009 Equity shares
17 Jul 2008 2.5 Final 21 Jul 2008 Equity shares
11 Jul 2007 2.5 Final 13 Jul 2007 Equity shares
20 Jul 2005 0.0 Final 22 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
12 Jul 2024 14.0 Final 13 Jul 2024 Equity shares
11 Jul 2023 10.0 Final 12 Jul 2023 Equity shares
14 Jul 2022 5.0 Final 15 Jul 2022 Equity shares
29 Jun 2021 3.0 Final 01 Jul 2021 Equity shares
10 Nov 2020 2.0 Interim 11 Nov 2020 Equity shares
18 Feb 2020 2.0 Interim 20 Feb 2020 Equity shares
27 Jun 2019 1.2 Final 29 Jun 2019 Equity shares
04 Aug 2016 2.0 Final 08 Aug 2016 Equity shares
06 Aug 2015 1.5 Final 08 Aug 2015 Equity shares
16 Jun 2014 1.5 Final 18 Jun 2014 Equity shares
16 Jun 2014 1.5 Special 18 Jun 2014 Equity shares
24 Jul 2013 1.2 Final 26 Jul 2013 Equity shares
13 Jul 2009 3.5 Final 15 Jul 2009 Equity shares
17 Jul 2008 2.5 Final 21 Jul 2008 Equity shares
11 Jul 2007 2.5 Final 13 Jul 2007 Equity shares
20 Jul 2005 0.0 Final 22 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

NEULAND LAB LTD. Share Price

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. Neuland Drugs & Pharmaceuticals Pvt. Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992. NLL manufactures bulk drugs.

The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr.

NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.

During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.

Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.

The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002.

The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003.

A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California.

During the year 2008-2009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.

During 2012-13, Company undertook a major reorganisation of businesses aimed at de-leveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its R&D activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates.

During 2013-14, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities.

In 2018, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited with the Company, on April 1, 2016, the Appointed Date of Scheme. Pursuant to the Scheme of Amalgamation, 45,90,608 equity shares held by Neuland Health Sciences Private Limited in the Company were cancelled and the Company allotted 68,61,243 equity shares to the shareholders of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited on April 13, 2018 and further 1,675,000 equity shares were issued and allotted under Qualified Institutional Placement (QIP).

The Company acquired multi product manufacturing facility Unit 3, with a capacity of about 197 kiloliters located at Gaddapotharam Village, in Sanga Reddy District, in 2018-19.

Parent organization Indian Private
NSE symbol NEULANDLAB
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Neuland Laboratories Ltd?

Answer Field

The share price of Neuland Laboratories Ltd for NSE is ₹ 11992 and for BSE is ₹ 12036.9.

What is the Market Cap of Neuland Laboratories Ltd?

Answer Field

The market cap of Neuland Laboratories Ltd for NSE is ₹ 1,53,85.60 Cr. and for BSE is ₹ 1,54,43.21 Cr. as of now.

What is the 52 Week High and Low of Neuland Laboratories Ltd?

Answer Field

The 52 Week High and Low of Neuland Laboratories Ltd for NSE is ₹ 18100.00 and ₹ 5540.10 and for BSE is ₹ 18089.55 and ₹ 5557.00.

How to Buy Neuland Laboratories Ltd share?

Answer Field

You can trade in Neuland Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Neuland Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 57.92%.

What is the Current Share Price of Neuland Laboratories Ltd?

Answer Field

Neuland Laboratories Ltd share price is for NSE ₹ 11992 & for BSE ₹ 12036.9 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Neuland Laboratories Ltd Share?

Answer Field

The market cap of Neuland Laboratories Ltd for NSE ₹ 1,53,85.60 & for BSE ₹ 1,54,43.21 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Neuland Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Neuland Laboratories Ltd share is 51.60.

What is the PB ratio of Neuland Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Neuland Laboratories Ltd share is 1081.52.

How to Buy Neuland Laboratories Ltd Share?

Answer Field

You can trade in Neuland Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Neuland Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Neuland Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Neuland Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|